Enanta Pharmaceuticals Inc (NASDAQ:ENTA) had a decrease of 1.68% in short interest. ENTA’s SI was 2.64M shares in February as released by FINRA. Its down 1.68% from 2.68 million shares previously. With 261,200 avg volume, 10 days are for Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s short sellers to cover ENTA’s short positions. The SI to Enanta Pharmaceuticals Inc’s float is 19.25%. The stock decreased 1.16% or $1.05 during the last trading session, reaching $89.58. About 124,060 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 56.90% since February 11, 2018 and is uptrending. It has outperformed by 56.90% the S&P500. Some Historical ENTA News: 28/03/2018 – Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018; 08/05/2018 – ENANTA 2Q REV. $44.0M, EST. $40.8M; 24/04/2018 – Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second; 21/05/2018 – Enanta at JMP Securities Life Sciences Conference Jun 20; 14/05/2018 – Stonepine Capital Management LLC Exits Position in Enanta; 12/04/2018 – Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress™ 2018; 08/05/2018 – ENANTA 2Q EPS 61C, EST. 53C; 19/03/2018 Enanta at Investor Day Hosted By H.C. Wainwright Today; 08/05/2018 – ENANTA PHARMACEUTICALS INC – ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MLN DUE TO INCREASE IN ABBVIE’S MAVYRET SALES; 22/04/2018 – DJ Enanta Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ENTA)
The stock of Companhia Brasileira de DistribuiÃ§Ã£o (NYSE:CBD) is a huge mover today! The stock decreased 1.47% or $0.37 during the last trading session, reaching $24.72. About 132,515 shares traded. Companhia Brasileira de DistribuiÃ§Ã£o (NYSE:CBD) has declined 6.64% since February 11, 2018 and is downtrending. It has underperformed by 6.64% the S&P500. Some Historical CBD News: 13/04/2018 – Brazil’s GPA says quarterly income rises 7.5 percent; 17/04/2018 – CASINO CFO SAYS SALE PROCESS FOR VIA VAREJO UNIT CONTINUES , NOTHING NEW TO REPORT AT THIS STAGE; 08/03/2018 – Retailer Casino’s efforts to revive profits fall flat with investors; 17/04/2018 – CASINO CASP.PA KEEPS 2018 FINANCIAL GOALS – CFO; 08/03/2018 Retailer Casino eyes further profit growth in 2018; 27/03/2018 – Amazon, Casino eye partnership or sale for electronics chain; 15/05/2018 – MONOPRIX CASP.PA EXPECTS TO MULTIPLY BY FIVE ITS ONLINE REVENUE IN NEXT THREE YEARS – MONOPRIX CEO SCHULTZ; 27/03/2018 – AMAZON-CASINO DEAL IN BRAZIL COULD BE STRUCTURED LIKE MONOPRIX PARTNERSHIP OR AS OUTRIGHT SALE OF VIA VAREJO; 17/04/2018 – CASINO CFO SAYS THERE ARE NO DISCUSSIONS WITH AMAZON REGARDING VIA VAREJO IN BRAZIL; 04/04/2018 – Apple Pay arrives in Brazil, partnering with ltaú UnibancoThe move comes after 9 months negative chart setup for the $6.58 billion company. It was reported on Feb, 11 by Barchart.com. We have $23.24 PT which if reached, will make NYSE:CBD worth $394.98M less.
Investors sentiment decreased to 1.29 in Q3 2018. Its down 0.21, from 1.5 in 2018Q2. It dropped, as 19 investors sold Enanta Pharmaceuticals, Inc. shares while 54 reduced holdings. 36 funds opened positions while 58 raised stakes. 16.15 million shares or 10.28% more from 14.64 million shares in 2018Q2 were reported. 707,113 are owned by Invesco Ltd. Alliancebernstein Limited Partnership holds 0% or 43,830 shares. Moreover, Teachers Retirement Systems Of The State Of Kentucky has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 3,989 shares. 15,728 are owned by Sei Co. Us Retail Bank De stated it has 315 shares or 0% of all its holdings. Rock Springs Mngmt Ltd Partnership has invested 0.29% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Quantbot Lp holds 1,170 shares or 0.01% of its portfolio. Comerica Bancshares holds 15,252 shares or 0.01% of its portfolio. Spark Mngmt Ltd Liability Com has invested 0.07% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Proshare Ltd Liability Company has invested 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Morgan Stanley accumulated 39,890 shares. California State Teachers Retirement reported 25,612 shares. State Of Alaska Department Of Revenue holds 0.01% or 5,082 shares in its portfolio. Element Cap Mngmt Limited stated it has 7,391 shares. Qs Invsts Ltd Liability Corporation owns 71,114 shares for 0.06% of their portfolio.
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.74 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 21.71 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.
More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharmaceuticals FQ3 revenue up 84% – Seeking Alpha” on February 06, 2019, also Nasdaq.com with their article: “ENTA Makes Bullish Cross Above Critical Moving Average – Nasdaq” published on February 08, 2019, Nasdaq.com published: “Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy? – Nasdaq” on January 30, 2019. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Benzinga.com and their article: “Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering – Benzinga” published on February 06, 2019 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings, IPOs (Feb. 3-9) – Benzinga” with publication date: February 03, 2019.
Since August 20, 2018, it had 0 buys, and 2 selling transactions for $779,632 activity. Adda Nathalie also sold $396,036 worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, September 20.
Companhia Brasileira de DistribuiÃ§Ã£o engages in the retail of food, clothing, home appliances, electronics, and other products through its chain of hypermarkets, supermarkets, specialized stores, and department stores primarily in Brazil. The company has market cap of $6.58 billion. The firm operates through two divisions, Food Retail; and Cash and Carry. It has a 22.85 P/E ratio. The Food retail segment sells non-perishable food products, beverages, fruits, vegetables, meat, breads, cold cuts, dairy products, cleaning products, disposable products, and personal care products; and non-food products, which include clothing items, baby items, shoes and accessories, household articles, books, magazines, CDs and DVDs, stationery, handcrafts, toys, sports and camping gears, furniture, mattresses, pet products, and gardening products, as well as electronic products, such as personal computers, software, computer accessories, and sound and image systems.
More notable recent Companhia Brasileira de DistribuiÃ§Ã£o (NYSE:CBD) news were published by: Benzinga.com which released: “CVS Corporation (NYSE:CVS), Kroger Company (The) (NYSE:KR) – CBD, Still A Restricted Substance – Benzinga” on January 23, 2019, also Fool.com with their article: “These 2 Pot Stocks Are Moving to the NYSE – The Motley Fool” published on January 13, 2019, Benzinga.com published: “What To Expect From Cannabis Stocks This Earnings Season (NYSE:ACB)(NYSE:CGC)(NASDAQ:CRON)(NASDAQ:TLRY) – Benzinga” on February 07, 2019. More interesting news about Companhia Brasileira de DistribuiÃ§Ã£o (NYSE:CBD) were released by: Seekingalpha.com and their article: “Green Growth Brands’ Offer For Aphria Stinks – Aphria Inc. (NYSE:APHA) – Seeking Alpha” published on February 07, 2019 as well as Fool.com‘s news article titled: “Better Marijuana Stock: Canopy Growth vs. KushCo Holdings – The Motley Fool” with publication date: February 09, 2019.
Analysts await Companhia Brasileira de DistribuiÃ§Ã£o (NYSE:CBD) to report earnings on February, 18. They expect $0.25 earnings per share, up 47.06% or $0.08 from last year’s $0.17 per share. CBD’s profit will be $66.58 million for 24.72 P/E if the $0.25 EPS becomes a reality. After $0.13 actual earnings per share reported by Companhia Brasileira de DistribuiÃ§Ã£o for the previous quarter, Wall Street now forecasts 92.31% EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.